Affinage · Toxoplasma gondii

BPK1

Rhoptry kinase family protein · UniProt S8FDR4

Annotated
2026-09-08
5 papers in source corpus 4 papers cited in narrative 7 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

BPK1 (bradyzoite pseudokinase 1) is a bradyzoite-specific component of the Toxoplasma gondii cyst wall that contributes to cyst wall integrity and oral transmissibility of the parasite (PMID:23291621). It resides in the cyst wall, where it co-immunoprecipitates with the wall proteins MAG1, MCP4, GRA8, and GRA9 (PMID:23291621) and is recovered in purified CST1-associated cyst wall fractions (PMID:31040239). Its stage-specific restriction to bradyzoites is enforced transcriptionally: the ApiAP2 factor AP2IV-4 represses BPK1 in replicating tachyzoites, and loss of AP2IV-4 drives ectopic BPK1 expression in tachyzoites (PMID:29718996). Functionally, deletion of BPK1 yields smaller cysts, cysts that are hypersensitive to pepsin-acid treatment, and a defect in establishing oral infection, while leaving in vitro cyst formation and initial intraperitoneal cyst burden intact (PMID:23291621). Comparative structural analysis places BPK1 in a basal ROP-kinase clade as a pseudokinase lacking the hallmarks of catalytic activity (PMID:23742205), so it likely acts as a structural or scaffolding element of the wall rather than a signaling enzyme; no direct biochemical activity or substrate has been characterized in the available corpus.

Mechanistic history

Synthesis pass · year-by-year structured walk · 5 steps
  1. 2013 Medium

    Establishing that BPK1 is a physical constituent of the cyst wall and defines its molecular neighborhood answered where and with what BPK1 acts.

    Evidence Co-immunoprecipitation from in vitro bradyzoite cultures identifying MAG1, MCP4, GRA8, and GRA9 as partners

    PMID:23291621

    Open questions at the time
    • Single Co-IP without reciprocal validation
    • Does not establish direct versus indirect associations
    • Stoichiometry and architecture of the complex unknown
  2. 2013 High

    Gene knockout with complementation tested whether BPK1 is functionally required, showing it is dispensable for cyst formation but needed for normal cyst size, wall integrity, and oral transmission.

    Evidence Δbpk1 knockout with complemented control assayed for in vitro/in vivo cyst formation, pepsin-acid resistance, and oral infection

    PMID:23291621

    Open questions at the time
    • Molecular basis of the wall-integrity defect unresolved
    • Whether smaller cyst size and transmission defect share a common mechanism unknown
    • No biochemical activity linked to the phenotype
  3. 2013 Low

    Comparative structural analysis addressed whether BPK1 is catalytically active, classifying it as a pseudokinase in a basal ROPK clade.

    Evidence Comparative sequence/structural analysis of ROPK family across T. gondii, N. caninum, and E. tenella

    PMID:23742205

    Open questions at the time
    • Computational only; pseudokinase status not confirmed biochemically
    • No test of residual catalytic or nucleotide-binding activity
    • Scaffolding function inferred, not demonstrated
  4. 2018 Medium

    Deleting the transcription factor AP2IV-4 answered how BPK1 stage-specificity is controlled, identifying it as an AP2IV-4-repressed target derepressed in tachyzoites.

    Evidence AP2IV-4 locus deletion with immunofluorescence/Western detection of BPK1 in tachyzoites

    PMID:29718996

    Open questions at the time
    • Does not establish direct promoter binding by AP2IV-4
    • Functional consequence of ectopic tachyzoite expression not assessed
  5. 2019 Medium

    Independent proteomics of purified cyst wall confirmed BPK1 localization, corroborating the original Co-IP-based assignment.

    Evidence Percoll-enriched, CST1-immunoprecipitated cyst wall analyzed by LC-MS/MS

    PMID:31040239

    Open questions at the time
    • Proteomic detection does not resolve submolecular position within the wall
    • Does not distinguish structural from regulatory role

Open questions

Synthesis pass · forward-looking unresolved questions
  • Whether BPK1 has any residual biochemical activity or a defined mechanistic role in wall assembly beyond being a structural/scaffolding component remains unresolved.
  • No direct biochemical assay of pseudokinase activity
  • Mechanism linking BPK1 loss to reduced wall integrity and transmission unknown
  • Direct versus indirect nature of partner interactions not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification
Partners
AP2IV-4 (TRANSCRIPTIONAL REPRESSOR)GRA8GRA9MAG1MCP4
Complex memberships
Cyst wall protein assembly with MAG1, MCP4, GRA8, GRA9

Evidence

Reading pass · 7 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 BPK1 is a cyst wall component that co-immunoprecipitates with at least four proteins: MAG1, MCP4, GRA8, and GRA9, from in vitro bradyzoite cultures. Immunoprecipitation from in vitro bradyzoite cultures followed by protein identification Eukaryotic cell Medium 23291621
2013 Deletion of BPK1 (Δbpk1) results in significantly smaller cysts at 8 weeks post-infection compared to parental and complemented strains, but no defect in in vitro cyst formation or cyst burden at 4 weeks post-intraperitoneal infection. Gene knockout (Δbpk1), in vitro and in vivo cyst formation assays, comparison with complemented strain Eukaryotic cell High 23291621
2013 BPK1 knockout cysts are significantly more sensitive to pepsin-acid treatment than parental or complemented strains, indicating BPK1 contributes to cyst wall integrity. Pepsin-acid treatment of in vivo cysts from Δbpk1, parental, and complemented strains Eukaryotic cell High 23291621
2013 Δbpk1 cysts show significantly reduced ability to establish oral infection compared to parental and complemented strains, demonstrating BPK1 is required for efficient oral transmission. Oral infection assay with Δbpk1 cysts in animal model, comparison with parental and BPK1-complemented strains Eukaryotic cell High 23291621
2013 Structural and evolutionary analysis classifies BPK1 as a pseudokinase belonging to a basal ROPK clade (termed ROPKL), sharing ROPK-specific conservation patterns including a hinge-region insert and a disulfide bridge in the substrate-binding lobe, but lacking features of active kinases. Comparative sequence and structural analysis of ROPK family members across Toxoplasma gondii, Neospora caninum, and Eimeria tenella genomes BMC evolutionary biology Low 23742205
2018 BPK1 expression in tachyzoites is suppressed by the ApiAP2 transcriptional repressor AP2IV-4; deletion of AP2IV-4 results in ectopic expression of BPK1 in replicating tachyzoites, establishing BPK1 as a transcriptional target of AP2IV-4. AP2IV-4 locus deletion with immunofluorescence/Western detection of BPK1 expression in tachyzoites PLoS pathogens Medium 29718996
2019 BPK1 was identified as a component of the purified cyst wall fraction by LC-MS/MS proteomics of CST1-immunoprecipitated cyst wall fragments, confirming its localization to the cyst wall. Cyst wall enrichment by Percoll gradient, CST1 antibody immunoprecipitation, and LC-MS/MS mass spectrometry mBio Medium 31040239

Source papers

Stage 0 corpus · 5 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis. PLoS pathogens 77 29718996
2013 Structural and evolutionary adaptation of rhoptry kinases and pseudokinases, a family of coccidian virulence factors. BMC evolutionary biology 69 23742205
2019 Enrichment and Proteomic Characterization of the Cyst Wall from In Vitro Toxoplasma gondii Cysts. mBio 65 31040239
2013 Bradyzoite pseudokinase 1 is crucial for efficient oral infectivity of the Toxoplasma gondii tissue cyst. Eukaryotic cell 41 23291621
2025 Role of Toxoplasma gondii p24δ in Regulating the Transition from Tachyzoite to Bradyzoite Development. International journal of molecular sciences 1 40244171